Announcement • Nov 07
Ambu A/S announces Annual dividend, payable on December 08, 2025 Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025. Announcement • Oct 01
Ambu A/S, Annual General Meeting, Dec 02, 2026 Ambu A/S, Annual General Meeting, Dec 02, 2026. Announcement • Aug 22
Ambu A/S Revises Financial Guidance for the Year 2024/25 Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%. Announcement • Jan 10
Ambu A/S Raises Financial Guidance for the Year 2024/25 Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). Announcement • Nov 08
Ambu A/S Proposes Dividend The Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year. Announcement • Sep 30
Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025 Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025 Reported Earnings • May 15
Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023) Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Jan 31
First quarter 2024 earnings released: EPS: kr.0.35 (vs kr.0.09 in 1Q 2023) First quarter 2024 results: EPS: kr.0.35 (up from kr.0.09 in 1Q 2023). Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Announcement • Dec 14
Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors Ambu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors. Board Change • Dec 01
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 18
Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors Ambu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors. Announcement • Nov 09
Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24 Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23. Reported Earnings • Sep 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in the United Kingdom. Board Change • Aug 16
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 12
Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023 Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%). Board Change • Jun 02
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 03
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 19% per year. Board Change • Apr 11
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 08
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022) First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Board Change • Feb 09
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 07
Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023 Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%. Board Change • Jan 06
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Shacey Petrovic was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 22
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Full year 2022 earnings released Full year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 11% per year. Board Change • Sep 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 12
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • May 06
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 16% growth forecast for the industry in the United Kingdom. Board Change • Apr 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 15% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 08
Upcoming dividend of kr.0.29 per share Eligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (2.1%). Reported Earnings • Nov 12
Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Reported Earnings • Aug 18
Third quarter 2021 earnings released The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr.973.0m (up 2.7% from 3Q 2020). Net income: kr.62.0m (down 33% from 3Q 2020). Profit margin: 6.4% (down from 9.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Board Change • Jul 30
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 03
Ambu A/S Revises Revenue Guidance for the Fiscal 2021 Ambu A/S revised revenue guidance for the fiscal 2021. The company expects organic revenue growth of approx. 17% compared to previously 17%-20%. Reported Earnings • May 13
Second quarter 2021 earnings released The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr.1.00b (up 1.2% from 2Q 2020). Net income: kr.95.0m (down 8.7% from 2Q 2020). Profit margin: 9.5% (down from 11% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • May 12
Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021 Ambu A/S reaffirmed earnings guidance for the fiscal year 2021. The company expects Organic growth in the range of 17% to 20%. Is New 90 Day High Low • Feb 16
New 90-day high: kr.331 The company is up 61% from its price of kr.206 on 17 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.266 per share. Announcement • Jan 29
Ambu A/S has completed a Follow-on Equity Offering in the amount of DKK 1.2345 billion. Ambu A/S has completed a Follow-on Equity Offering in the amount of DKK 1.2345 billion.
Security Name: B Shares
Security Type: Common Stock
Securities Offered: 4,711,832
Price\Range: DKK 262
Transaction Features: Subsequent Direct Listing Analyst Estimate Surprise Post Earnings • Jan 28
Revenue beats expectations Revenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 14%, compared to a 10% growth forecast for the Medical Equipment industry in the United Kingdom. Is New 90 Day High Low • Jan 28
New 90-day high: kr.310 The company is up 60% from its price of kr.194 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.263 per share. Reported Earnings • Jan 28
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr.1.01b (up 33% from 1Q 2020). Net income: kr.91.0m (up 117% from 1Q 2020). Profit margin: 9.0% (up from 5.5% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Announcement • Jan 27
Ambu A/S to Report Fiscal Year 2021 Results on Nov 09, 2021 Ambu A/S announced that they will report fiscal year 2021 results on Nov 09, 2021 Is New 90 Day High Low • Dec 30
New 90-day high: kr.263 The company is up 44% from its price of kr.183 on 01 October 2020. The British market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.265 per share. Is New 90 Day High Low • Dec 14
New 90-day high: kr.212 The company is up 25% from its price of kr.170 on 15 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.66.63 per share. Upcoming Dividend • Dec 03
Upcoming Dividend of kr.0.29 Per Share Will be paid on the 14th of December to those who are registered shareholders by the 10th of December. The trailing yield of 0.1% is below the top quartile of British dividend payers (4.8%), and is lower than industry peers (1.9%). Announcement • Oct 10
Ambu A/S Announces Board Changes Lars Rasmussen, who has been chairman of the Board of Directors in Ambu A/S since December 2019, has decided not to seek re-election at the Annual General Meeting in December 2020. Oliver Johansen, who has been a member of the Board in Ambu A/S since 2015 and who is SVP, Global R&D with Coloplast, has also decided not to seek re-election at the Annual General Meeting for the same reason as Lars Rasmussen.